Medical genetics-based drug repurposing for Alzheimer's disease

Brain Research Bulletin

Volumn 110, Issue , 2015, Pages 26-29

  Zhang, Xiu Zhen ^a   Quan, Yuan ^b   Tang, Guang Yan ^b  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Angiotensin converting enzyme inhibitors; Drug repurposing; Medical genetics

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NOOTROPIC AGENT;

ALZHEIMER DISEASE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG REPOSITIONING; DRUG TARGETING; GENOMICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL GENETICS; PHARMACOGENETICS; REVIEW; ANIMAL; GENETICS; PROCEDURES;

ALZHEIMER DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DRUG REPOSITIONING; HUMANS; NOOTROPIC AGENTS;

EID: 84918839466     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2014.11.003     Document Type: Review

References (49)

1. AbdAlla S., Langer A., Fu X., Quitterer U. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease. Int. J. Mol. Sci. 2013, 14(8):16917-16942.
2. Arregui A., Perry E.K., Rossor M., Tomlinson B.E. Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J. Neurochem. 1982, 38(5):1490-1492.
3. Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004, 3(8):673-683.
4. Appleby B.S., Cummings J.L. Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr. Top. Med. Chem. 2013, 13:2306-2327.
5. Barnes N.M., Cheng C.H., Costall B., Naylor R.J., Williams T.J., Wischik C.M. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur. J. Pharmacol. 1991, 200(2-3):289-292.
6. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39(1):17-23.
7. Brinkman R.R., Dubé M.P., Rouleau G.A., Orr A.C., Samuels M.E. Human monogenic disorders - a source of novel drug targets. Nat. Rev. Genet. 2006, 7(4):249-260.
8. Brookmeyer R., Evans D.A., Hebert L., Langa K.M., Heeringa S.G., Plassman B.L., Kukull W.A. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's Dement. 2011, 7(1):61-73.
9. Casado A., López-Fernández M.E., Casado M.C., de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem. Res. 2008, 33(3):450-458.
10. Coates D. The angiotensin converting enzyme (ACE). Int. J. Biochem. Cell Biol. 2003, 35(6):769-773.
11. Corbett A., Pickett J., Burns A., Corcoran J., Dunnett S.B., Edison P., Hagan J.J., Holmes C., Jones E., Katona C., et al. Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov. 2012, 11(11):833-846.
12. Corbett A., Ballard C. Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?. Expert Opin. Investig. Drugs 2013, 22:941-943.
13. Cummings J.L., Zhong K. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Rev. Clin. Pharmacol. 2014, 7:161-165.
14. Das U.N. Angiotensin-II behaves as an endogenous pro-inflammatory molecule. J. Assoc. Physicians India 2005, 53:472-476.
15. Dong Y.F., Kataoka K., Kataoka K., Tokutomi Y., Nako H., Nakamura T., Toyama K., Sueta D., Koibuchi N., Yamamoto E., Ogawa H., et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J. 2011, 25(9):2911-2920.
16. Danilova Y.V., Shagimardanova E.I., Margulis A.B., Toymentseva A.A., Balaban N.P., Rudakova N.L., Rizvanov A.A., Sharipova M.R., Palotas A. Bacterial enzymes effectively digest Alzheimer's beta-amyloid peptide. Brain Res. Bull. 2014, 108C:113-117.
17. Dias Fiuza Ferreira E., Valerio Romanini C., Cypriano P.E., Weffort de Oliveira R.M., Milani H. Sildenafil provides sustained neuroprotection in the absence of learning recovery following the 4-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion in middle-aged rats. Brain Res. Bull. 2013, 90:58-65.
18. Gao Y., O'Caoimh R., Healy L., Kerins D.M., Eustace J., Guyatt G., Sammon D., Molloy D.W. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013, 3:e002881.
19. Helmuth L. New therapies. New Alzheimer's treatments that may ease the mind. Science 2002, 297(5585):1260-1262.
20. Hemming M.L., Selkoe D.J., Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 2007, 26(1):273-281.
21. Hemming M.L., Selkoe D.J. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem. 2005, 280(45):37644-37650.
22. Jin G., Wong S.T. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov. Today 2014, 19(5):637-644.
23. Katzov H., Bennet A.M., Kehoe P., Wiman B., Gatz M., Blennow K., Lenhard B., Pedersen N.L., de Faire U., Prince J.A. A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. Hum. Mol. Genet. 2004, 13(21):2647-2657.
24. Kehoe P.G., Wilcock G.K. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol. 2007, 6:373-378.
25. Landreth G., Jiang Q., Mandrekar S., Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
26. Lehmann D.J., Cortina-Borja M., Warden D.R., Smith A.D., Sleegers K., Prince J.A., van Duijn C.M., Kehoe P.G. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am. J. Epidemiol. 2005, 162(4):305-317.
27. Maxwell C.J., Hogan D.B. Antihypertensive agents and prevention of dementia. BMJ 2010, 340:b5409.
28. Meamar R., Dehghani L., Ghasemi M., Saadatnia M., Basiri K., Faradonbeh N.A., Javanmard S.H. Enalapril protects endothelial cells against induced apoptosis in Alzheimer's disease. J. Res. Med. Sci. 2013, 18(Suppl. 1):S1-S5.
29. Ohrui T., Matsui T., Yamaya M., Arai H., Ebihara S., Maruyama M., Sasaki H. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J. Am. Geriatr. Soc. 2004, 52(4):649-650.
30. Ohrui T., Tomita N., Sato-Nakagawa T., Matsui T., Maruyama M., Niwa K., Arai H., Sasaki H. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004, 63(7):1324-1325.
31. O'Caoimh R., Healy L., Gao Y., Svendrovski A., Kerins D.M., Eustace J., Kehoe P.G., Guyatt G., Molloy D.W. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. J. Alzheimer's Dis. 2014, 40:595-603.
32. Radak Z., Zhao Z., Goto S., Koltai E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol. Aspects Med. 2011, 32:305-315.
33. Savaskan E., Hock C., Olivieri G., Bruttel S., Rosenberg C., Hulette C., Muller-Spahn F. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol. Aging 2001, 22(4):541-546.
34. Shah K., Qureshi S.U., Johnson M., Parikh N., Schulz P.E., Kunik M.E. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J. Geriatr. Pharmacother. 2009, 7(5):250-261.
35. Singh B., Sharma B., Jaggi A.S., Singh N. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-(agonistic property. J. Renin Angiotensin Aldosterone Syst. 2013, 14(2):124-136.
36. Sink K.M., Leng X., Williamson J., Kritchevsky S.B., Yaffe K., Kuller L., Yasar S., Atkinson H., Robbins M., Psaty B., et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study?. Arch. Intern. Med. 2009, 169(13):1195-1202.
37. Soto M.E., van Kan G.A., Nourhashemi F., Gillette-Guyonnet S., Cesari M., Cantet C., Rolland Y., Vellas B. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Reseau sur la Maladie d'Alzheimer Francais cohort. J. Am. Geriatr. Soc. 2013, 61:1482-1488.
38. Tian M., Zhu D., Xie W., Shi J. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett. 2012, 586(20):3737-3745.
39. Varga J., Klausz B., Domokos A., Kalman S., Pakaski M., Szucs S., Garab D., Zvara A., Puskas L., Kalman J., et al. Increase in Alzheimer's related markers preceeds memory disturbances: studies in vasopressin-deficient Brattleboro rat. Brain Res. Bull. 2014, 100:6-13.
40. Wang Z.Y., Zhang H.Y. Rational drug repositioning by medical genetics. Nat. Biotechnol. 2013, 31(12):1080-1082.
41. Wang X., Wei X., Thijssen B., Das J., Lipkin S.M., Yu H. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat. Biotechnol. 2012, 30(2):159-164.
42. Wang Z.Y., Fu L.Y., Zhang H.Y. Can medical genetics and evolutionary biology inspire drug target identification?. Trends Mol. Med. 2012, 18(2):69-71.
43. Wang Z.Y., Quan Y., Zhang H.Y. Medical genetic inspirations for anticancer drug repurposing. Trends Pharmacol. Sci. 2014, 35(1):1-3.
44. Wimo A., Prince M. World Alzheimer Report 2010: The Global Economic Impact of Dementia 2011, Alzheimer's Disease International.
45. Yamada K., Uchida S., Takahashi S., Takayama M., Nagata Y., Suzuki N., Shirakura S., Kanda T. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res. 2010, 1352:176-186.
46. Yang W.N., Han H., Hu X.D., Feng G.F., Qian Y.H. The effects of perindopril on coognitive impairment induced by d-galactose and aluminum trichloride via inhibition of acetylcholinesterase activity and oxidative stress. Pharmacol. Biochem. Behav. 2013, 114-115:31-36.
47. Yulug B., Hanoglu L., Kilic E., Schabitz W.R. RIFAMPICIN: an antibiotic with brain protective function. Brain Res. Bull. 2014, 107:37-42.
48. Zhu D., Shi J., Zhang Y., Wang B., Liu W., Chen Z., Tong Q. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS ONE 2011, 6(1):e16037.
49. Zimmerman M.C., Lazartigues E., Lang J.A., Sinnayah P., Ahmad I.M., Spitz D.R., Davisson R.L. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ. Res. 2002, 91(11):1038-1045.